News coverage about Enzymotec (NASDAQ:ENZY) has been trending positive on Friday, AlphaOne reports. AlphaOne, a unit of Accern, identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzymotec earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Alpha One Sentiment Analysis’s analysis:
- Enzymotec Reports First Quarter 2017 Unaudited Financial Results (biospace.com)
- Enzymotec Ltd (NASDAQ:ENZY) reported earnings of $0.03 per share missing Walls Streets expectations. (4-traders.com)
- Enzymotec Ltd (ENZY) Posts Earnings Results, Misses Expectations By $0.03 EPS (americanbankingnews.com)
- Investor Network: Enzymotec Ltd. to Host Earnings Call (finance.yahoo.com)
- Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results (finance.yahoo.com)
Shares of Enzymotec (NASDAQ:ENZY) remained flat at $8.25 during mid-day trading on Friday. 2,195 shares of the stock traded hands. The firm’s 50 day moving average price is $8.56 and its 200 day moving average price is $7.83. Enzymotec has a one year low of $5.20 and a one year high of $9.32. The stock’s market capitalization is $188.92 million.
Enzymotec (NASDAQ:ENZY) last issued its earnings results on Wednesday, May 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The firm had revenue of $12 million during the quarter, compared to analysts’ expectations of $14.23 million. Enzymotec had a return on equity of 1.95% and a net margin of 4.82%. The firm’s quarterly revenue was down 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.09 EPS. Equities analysts forecast that Enzymotec will post $0.26 earnings per share for the current fiscal year.
A number of brokerages have issued reports on ENZY. Jefferies Group LLC reissued a “hold” rating and set a $8.00 target price on shares of Enzymotec in a research note on Thursday, February 23rd. Zacks Investment Research downgraded shares of Enzymotec from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 1st.
ILLEGAL ACTIVITY WARNING: This piece was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/05/19/enzymotec-enzy-receives-daily-news-sentiment-rating-of-0-31-updated.html.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd and related companies with MarketBeat.com's FREE daily email newsletter.